Cantor Fitzgerald restated their overweight rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a report released on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $4.00 price target on the stock. Cantor Fitzgerald also issued estimates for Lucid Diagnostics’ FY2023 earnings at ($1.14) EPS and FY2024 earnings at ($0.82) EPS. Separately, […]
Lucid Diagnostics Inc. (NASDAQ:LUCD – Free Report) – Equities researchers at Cantor Fitzgerald raised their FY2023 EPS estimates for shares of Lucid Diagnostics in a research report issued on Thursday, August 17th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($1.14) for the year, up from their […]
NovoCure (NASDAQ:NVCR – Get Free Report) and Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Volatility and Risk NovoCure has a beta of 0.6, […]
NovoCure (NASDAQ:NVCR – Get Free Report) and Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability. Risk and Volatility NovoCure has a beta of 0.6, […]
NovoCure (NASDAQ:NVCR – Get Free Report) and Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings. Profitability This table compares NovoCure and Lucid Diagnostics’ net […]